Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 0.56% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 0.56% year-over-year, with the annual reading at $9.5 million for FY2025, 0.56% down from the prior year.
  • Other Non-Current Liabilities hit $9.5 million in Q4 2025 for Vanda Pharmaceuticals, down from $11.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $11.0 million in Q3 2025 to a low of $1.0 million in Q1 2022.
  • Historically, Other Non-Current Liabilities has averaged $6.7 million across 5 years, with a median of $6.7 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 61.09% in 2022 and later skyrocketed 540.08% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $4.4 million in 2021, then skyrocketed by 54.9% to $6.8 million in 2022, then increased by 29.81% to $8.8 million in 2023, then grew by 8.61% to $9.6 million in 2024, then dropped by 0.56% to $9.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for VNDA at $9.5 million in Q4 2025, $11.0 million in Q3 2025, and $10.0 million in Q2 2025.